Bethesda Hospital East

Clinical Trials

Receiving Tomorrow's Treatments Today at Bethesda

When you're looking for the most advanced drug treatments available, turn to the clinical research experts at the Bethesda Research Center.

These clinical trials are listed for informational purposes, and are not to be used outside of a clinical trial setting. Please contact the Bethesda Research Center at 561.374.5020 for full particulars regarding enrollment of any clinical trial.



Study Type: 

1.    Pancreatic Cancer

»  Principal Investigator:    Rogelio Brito, D.O.

•  Study Title:     A randomized, multicenter, double-blind, placebo-controlled, Phase 2/3 study of the Bruton’s Tyrosine Kinase inhibitor ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine, in the first line treatment of patients with metastatic pancreatic adenocarcinoma

°  Study Summary:    If you have been recently diagnosed with Stage IV Pancreatic Cancer, you may be eligible to take part in a clinical research study called PCYC-1137CA. To be a potential participant you must have untreated metastatic pancreatic adenocarcinoma and your doctor must believe that you will be suitable for treatment with nab-paclitaxel and gemcitabine, which are two of the drugs being studied.

°  Study Objective:    The purpose of this study is to learn whether giving three drugs together works better than giving just two drugs in treating pancreatic adenocarcinoma.


2.    Cardiovascular Revascularization:

»  Principal Investigator:     George Mueller, M.D.

•  Study Title:         A prospective, Multicenter, Single arm, Real-World Registery Assessing the Clinical use of the Lutonix® 035 Drug Coated Ballon Catheter in Artheries of the Superficial Femoral Artery and Polpliteal Atery

°  Study Summary:    If your doctor is planning to treat a blockage, or stenosis, in your superficial femoral artery or popliteal artery, you may qualify to take part in a study called SAFE-DCB U.S. Registry.

°  Study Objective:    The purpose of this patient registry is to access the safety and usage of the FDA already approved Lutonix® DCB PTA catheter. 

3.    Cardiovascular Heart Failure:

»  Principal Investigator:    George Daniel, M.D

•  Study Title:        ARTEMIS - Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study 

°  Study Summary:    If you are currently hospitalized with STEMI/NSTEMI (Heart Attack) symptoms and given blood thinning medication, you could qualify to take part in this trial. 

°  Study Objective:    The purpose of this study is to learn about the impact of medication copayments on how patients take antiplatelet medications after hospital discharge, and how this influences patients’ long term health and us of healthcare resources.


4.    Cardiovascular Chronic Heart Failure:

»  Principal Investigator:    George Daniel, M.D

•  Study Title:        A Double-blind, Randomized, Sham–procedure–controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (rexlemestrocel-L) in Patients with Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic or Nonischemic Etiology

°  Study Summary:    If you are between 18 to 80 years of age and currently suffering from chronic heart failure, you may be eligible to take part in a clinical research study called DREAM HF-1.

°  Study Objective:    The purpose of this study is to evaluate the efficacy and safety of a single cardiac catheterization involving transendocardial delivery of human bone marrow allogeneic  (rexlemestrocel-L) in improving clinical outcomes, preventing cardiac remodeling, and increasing exercise capacity in patient with chronic HF due to LV systolic dysfunction of either ishemic or nonischemic etiology who have received optimal medical/revascularization therapy.



5.    Acute Coronary Syndrome:

»  Principal Investigator:    George Daniel, M.D

•  Study Title:        A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The dal-GenE trial.

°  Study Summary:    You may be eligible to take part in this study if you were recently hospitalized for an ACS (Heart Attack) or ischemia, and were told by your physician that you have a high risk of experiencing another cardiovascular event.

°  Study Objective:    The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce cadrdiovascular morbidity and mortality in subjects with a documented recent ACS and the AA genotype of variant rs1967309 in the ADCY9gene.


6.    Cardiovascular Disease:

»  Principal Investigator:    Rachel Eidelman, M.D

•  Study Title:    A randomized, double blind controlled factorial clinical trial of edetate disodium-based chelation and high-dose oral vitamins and minerals to prevent recurrent cardiac events in diabetic patients with a prior myocardial infarction (MI).

°  Study Summary:     If you are a diabetic male or female, 50 years of age or older with a history of an MI (heart attack), you may be eligible to take part in a clinical research study called TACT2.

°  Study Objective:      The primary objective of TACT2 to replicate the findings of TACT1, which found a striking reduction of recurrent cardiovascular events in post-MI diabetic patients receiving edetate disodium-based chelation therapy. 


Contact Us

The Bethesda Research Center is located in the Bethesda Professional Plaza, next to Bethesda Hospital East. For full particulars regarding enrollment of any clinical trial, call 561.374.5020.